title: Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design.
authors.affiliation: Drug Discovery and Development, Ribapharm Inc, 3300 Hyland Avenue, Costa Mesa, CA 92626, USA. jwu@ribapharm.com
authors.forename: Jim Zhen
authors.initials: JZ
authors.lastname: Wu
authors.forename: Chin-chung
authors.initials: CC
authors.lastname: Lin
authors.forename: Zhi
authors.initials: Z
authors.lastname: Hong
mesh_terms: D000243:Adenosine Deaminase / Q000008:administration & dosage* / Q000737:chemistry; D000818:Animals; D002384:Catalysis / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D009705:Nucleosides / Q000008:administration & dosage / Q000138:chemical synthesis; D011355:Prodrugs / Q000008:administration & dosage* / Q000138:chemical synthesis; D012254:Ribavirin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry
chemical_list: D009705:Nucleosides; D011355:Prodrugs; D012254:Ribavirin; D000243:Adenosine Deaminase; C026956:taribavirin